Brief: Achieve Life Sciences Announces Submission Of NDA To FDA For Cytisinicline As Treatment Of Nicotine Dependence For Smoking Cessation
26/06/2025 21:59
June 26 (Reuters) - Achieve Life Sciences Inc ACHV.O: ACHIEVE LIFE SCIENCES ANNOUNCES SUBMISSION OF NDA TO FDA FOR CYTISINICLINE AS A TREATMENT OF NICOTINE DEPENDENCE FOR SMOKING CESSATION Source text: ID:nGNX85FLs1 Further company coverage: ACHV.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Achieve Life Sciences
See all newsAchieve Life Sciences Q3 net loss and loss per share beat estimates
Brief: Achieve Life Sciences Presents 52-Week Cytisinicline Results For Smoking And Vaping Cessation At Chest 2026
Brief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Achieve Life Sciences Appoints Kaitlyn Tuson As Senior Vice President, Marketing And Communications
Brief: Achieve Life Sciences - Enters ATM Sale Agreement With Jefferies For Up To $150 Million In Common Stock